Granisetron Transdermal Patch and Vemurafenib: Interaction Details

Brand names
Granisetron Transdermal Patch
SancusoSustolGranisol
Vemurafenib
Zelboraf
Dr. Brian Staiger, PharmD, BCPS

Medically reviewed by ⁠

Also reviewed by the HelloPharmacist Editorial Team Updated AI-assisted Details about this page

A close look at the Granisetron Transdermal Patch and Vemurafenib interaction:

Share

Share this interaction

Granisetron Transdermal Patch

Brand names
  • Sancuso
  • Sustol
  • Granisol

What Happens When You Take Granisetron Transdermal Patch With Vemurafenib

What can happen when they are taken together (rated Major)

Increased risk of

Interaction Deep Dive

A note from Dr. Brian Staiger If you’re a patient, this deep dive may be too technical, or bore you (or both). Read the plain-language explanation →

Vemurafenib should not be initiated in patients who are already taking another medication known to lengthen the . Because vemurafenib itself prolongs the QT interval, it can raise the risk of serious cardiac adverse events, among them. When it is given together with another QT-prolonging drug, the effects on the QT interval may be , which further elevates the risk of torsade de pointes.1

The Granisetron Transdermal Patch and Vemurafenib Interaction, Explained

Vemurafenib (Zelboraf) is a melanoma medicine that can slow the heart's electrical recharging time, called the . Granisetron (the Sancuso patch) prevents nausea from chemotherapy and can have a similar effect on the heart. Taken together, these effects could add up and raise the chance of a dangerous heart rhythm problem called .

This concern is mostly based on how the drugs work, not on many reported cases. Still, it is taken seriously. Please don't stop or change either medicine on your own. Tell your pharmacist or doctor you use both, and report fainting, dizziness, or a racing or fluttering heartbeat right away. Your care team can weigh the options and monitor you.

Mechanism: (). Vemurafenib has a known QT-prolonging effect, and granisetron (5-HT3 ) is also associated with QT prolongation. Neither relies on a pathway here, so the concern is additive risk rather than altered exposure.

  • Risk: Increased risk of and serious cardiac events.
  • Evidence: Theoretical; onset unspecified. Transdermal delivery gives lower peak concentrations, but the risk is not eliminated.
  • Management: Labeling advises against starting vemurafenib in patients taking another QT-prolonging drug. If is unavoidable, consider an alternative antiemetic, and the team may monitor and electrolytes (K, Mg) more closely and individualize therapy.

See the 1 reference behind this explanation ↓

From the HelloPharmacist Pharmacy Team

AI-assisted: written with AI from this pair’s record in our interaction database, and reviewed by the HelloPharmacist pharmacy team. Written .

How we build these pages · How we use AI · Our editorial policy

Why Granisetron Transdermal Patch and Vemurafenib Interact

The likely mechanism


In short: Granisetron transdermal patch and vemurafenib both lengthen the QT interval, a measure of the heart’s rhythm, so taken together the effect can add up.
How Drug Interactions Work See this kind of interaction drawn out, step by step, in “When Effects Add Up or Cancel Out”, one chapter of our one-minute explainer. See how it works 

How to Manage the Granisetron Transdermal Patch and Vemurafenib Interaction

Your care team will usually review your full medicine list before starting vemurafenib. The documented advice is not to start vemurafenib while someone is taking another drug that prolongs the , so your team may consider an alternative to the granisetron patch or tailor your plan and monitor you more closely.

  • Keep taking your medicines as prescribed until your care team tells you otherwise.
  • Tell your pharmacist and prescriber about every medicine and supplement you use.
  • Ask whether heart monitoring is right for you.
  • Report fainting, severe dizziness, or an irregular heartbeat right away.

Management is individual — confirm any change with your pharmacist or prescriber.

Questions for Your Pharmacist

  • Does my dose of Granisetron Transdermal Patch or Vemurafenib need adjusting while I take them together?
  • What symptoms should prompt me to call you or my prescriber right away?
  • Does the timing of my doses matter for this combination?
  • Is there another option that avoids this interaction?

Granisetron Transdermal Patch and Vemurafenib: Common Questions

How serious is the Granisetron Transdermal Patch and Vemurafenib interaction?

It is rated major. Potentially serious — often needs a change or close monitoring.

How is the Granisetron Transdermal Patch and Vemurafenib interaction managed?

Your care team will usually review your full medicine list before starting vemurafenib. The documented advice is not to start vemurafenib while someone is taking another drug that prolongs the , so your team may consider an alternative to the granisetron patch or tailor your plan and monitor you more closely. Keep taking your medicines as prescribed until your care team tells you otherw… Management is individual — always follow your own care team's guidance.

Is there an alternative to taking Granisetron Transdermal Patch with Vemurafenib?

The documented advice is not to start vemurafenib while someone is taking another drug that prolongs the , so your team may consider an alternative to the granisetron patch or tailor your plan and monitor you more closely. The record names this example:

Only your prescriber can decide whether a change fits you, so talk with them before changing either medicine.

How quickly could this interaction happen?

The documented onset is "unspecified". The timing of this interaction is not well characterized.

How strong is the evidence for this interaction?

The evidence is graded "theoretical". Expected from how the drugs work, or from studies of similar drugs; this exact pair has little direct study.

Ask About the Granisetron Transdermal Patch and Vemurafenib Interaction

Ask in your own words about taking Granisetron Transdermal Patch and Vemurafenib together. The answer comes from this page’s interaction record and both drugs’ own information.

This box answers questions about this one combination only. For anything else about either drug, open its drug information page or ask a pharmacist.

Try:

AI answers from this page’s record and both drugs’ information, never the open internet. AI can make mistakes, so always check with your doctor or pharmacist.

References (1)

  1. Product Information: ZELBORAF(R) oral tablets, vemurafenib oral tablets. Genentech USA, Inc. (per FDA), South San Francisco, CA, 2016. DailyMed
Was this write-up helpful?

Other Serious Interactions of Granisetron Transdermal Patch and Vemurafenib

Also serious with Granisetron Transdermal Patch

Also serious with Vemurafenib

These Medications Also Interact With Supplements

Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:

With Vemurafenib

Check everything you take with our drug–supplement interaction checker.

Still Have Questions About This Combination?

Every question gets a real answer from a licensed pharmacist — free, as soon as they can.

About This Library

Built in-house, documented one interaction at a time. Our interaction database is not a complete list of every known interaction: a combination that isn't listed here hasn't been documented by us yet, which never means it's safe. Checking everything you take at once? Ask your pharmacist to review your full medication list. How we build and review it →

What Each Rating Means

Severity Levels

  • Contraindicated These should generally not be used together.
  • Major Potentially serious — often needs a change or close monitoring. This interaction.
  • Moderate Can be significant — usually manageable with monitoring.
  • Minor Usually limited clinical impact.

Evidence Grades

  • EstablishedWell documented — supported by controlled studies or strong clinical data.
  • ProbableGood supporting evidence, though not definitively proven.
  • SuspectedSome evidence suggests this interaction, but it is not well established.
  • PossibleLimited or conflicting evidence; the interaction may occur.
  • TheoreticalExpected from how the drugs work, or from studies of similar drugs; this exact pair has little direct study. This interaction.

How Soon It Shows

  • RapidEffects can appear quickly, often within about 24 hours of combining the drugs.
  • DelayedEffects tend to build up gradually over days to weeks.
  • UnspecifiedThe timing of this interaction is not well characterized. This interaction.

Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.

Back to the answer
This information is for education, not a substitute for professional medical advice. Do not start, stop, or change any medication without talking to your pharmacist or prescriber.